London, UK – GHO Capital, the European specialist investor in healthcare, has acquired a majority stake in Validant, a leading quality, compliance and regulatory affairs consulting firm.
Operating globally with offices in Europe and North America, Validant provides specialist consulting services, with a focus on quality, compliance and regulatory affairs, to a broad range of clients across the biotech, pharma and medtech sectors.
Founded in 2005, Validant has established itself as a leader in its specialist field, providing tailored expert teams to solve critical customer challenges. With an unparalleled expert consultant network, Validant focuses on being highly responsive to unique and complex customer needs. The Company boasts an exceptional track record, having advised 20 of the top 30 Global Pharmaceutical firms, 25 of the top 30 Medical Device firms, and 7 of the top 10 Biotechnology firms globally.
Validant operates in a high growth market, driven by continued focus on patient safety and product quality from manufacturers and global regulatory bodies alike, as well as the increased penetration of specialist outsourced providers serving the industry. The Company is achieving rapid international growth, supporting customers on five continents as they navigate across multiple markets in an increasingly complex regulatory environment.
GHO Capital brings deep sectoral expertise and networks to support Validant’s senior management team in accelerating international growth organically and through selective acquisitions as well as to help broaden the service offering. In a highly fragmented marketplace, Validant offers a proven, differentiated platform for growth.